Erythrocytosis refers to an abnormal increase in red blood cell mass, and is the most common adverse effect of TRT affecting up to 40% of patients. Testosterone directly stimulates erythropoietin (EPO) production in the kidneys, driving red cell synthesis. Secondary erythrocytosis from TRT is distinct from primary polycythemia vera but carries similar thrombotic risk when hematocrit exceeds 52–54%.
GearCheck connects glossary concepts to your actual bloodwork — showing exactly where your values sit and what they mean in the context of your protocol.
Analyze My Bloodwork →GearCheck provides blood marker analysis and harm reduction education. Information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional.